Overview

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2001-06-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of etoposide plus radiation therapy followed by peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Temple University
Collaborator:
Fox Chase Cancer Center
Treatments:
Cyclophosphamide
Etoposide
Criteria
DISEASE CHARACTERISTICS: Pathologically confirmed non-Hodgkin's lymphomas of the following
histologic subtypes: Small lymphocytic Follicular small cleaved cell Follicular mixed cell
Follicular large cell (relapsed) Disease in first, second, or third partial remission (25%
shrinkage in cross-sectional area of measurable disease) or first, second, or subsequent
relapse required Transformed non-Hodgkin's lymphoma eligible, i.e., low-grade lymphoma
subsequently transformed to intermediate- or high-grade lymphoma No lymphosarcoma cell
leukemia

PATIENT CHARACTERISTICS: Age: 16 to 65 Performance status: Karnofsky 80-100% Hematopoietic:
WBC at least 5,000/mm3 (polys at least 2,000/mm3) Platelet count at least 100,000/mm3
Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT no greater than 2 times normal Renal:
Creatinine no greater than 1.8 mg/dL Cardiovascular: LVEF at least 50% Pulmonary: FVC
greater than 1.5 liters FEV1 greater than 1.2 liters MVV greater than 50 liters DLCO
greater than 12 mL/min pO2 greater than 70 mm Hg on room air Other: No other serious
psychiatric, neurologic, or medical illness

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: Not specified Radiotherapy: Less than 3,500 cGy prior irradiation to the
mediastinum, lungs, or spinal cord Surgery: Not specified